Elizabeth Alli to Humans
This is a "connection" page, showing publications Elizabeth Alli has written about Humans.
Connection Strength
0.158
-
Alli E, Ford JM. BRCA1: Beyond double-strand break repair. DNA Repair (Amst). 2015 Aug; 32:165-171.
Score: 0.027
-
Alli E, Solow-Cordero D, Casey SC, Ford JM. Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair. Cancer Res. 2014 Nov 01; 74(21):6205-15.
Score: 0.026
-
Alli E, Ford JM. Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol. DNA Repair (Amst). 2012 May 01; 11(5):522-4.
Score: 0.022
-
Alli E, Sharma VB, Sunderesakumar P, Ford JM. Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res. 2009 Apr 15; 69(8):3589-96.
Score: 0.018
-
Alli E, Yang JM, Ford JM, Hait WN. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol. 2007 May; 71(5):1233-40.
Score: 0.015
-
Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene. 2007 Feb 15; 26(7):1003-12.
Score: 0.015
-
Alli E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res. 2002 Dec 01; 62(23):6864-9.
Score: 0.012
-
Liang Y, Dearnaley WJ, Alden NA, Solares MJ, Gilmore BL, Pridham KJ, Varano AC, Sheng Z, Alli E, Kelly DF. Correcting errors in the BRCA1 warning system. DNA Repair (Amst). 2019 01; 73:120-128.
Score: 0.009
-
Vinayak S, Schwartz EJ, Jensen K, Lipson J, Alli E, McPherson L, Fernandez AM, Sharma VB, Staton A, Mills MA, Schackmann EA, Telli ML, Kardashian A, Ford JM, Kurian AW. A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast Cancer Res Treat. 2013 Nov; 142(2):389-98.
Score: 0.006
-
Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010 Oct 15; 70(20):7970-80.
Score: 0.005
-
Bash-Babula J, Toppmeyer D, Labassi M, Reidy J, Orlick M, Senzon R, Alli E, Kearney T, August D, Shih W, Yang JM, Hait WN. A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4. Clin Cancer Res. 2002 May; 8(5):1057-64.
Score: 0.003